Effect of statin use on survival in patients with endometrial cancer.

Abstract

e17641 Background: Statin use has been found to reduce cancer related mortality in multiple cancer types. Prior studies have not specifically studied endometrial cancer independently from other tumors. This study investigates concurrent statin use on cancer related mortality in patients diagnosed with endometrial cancer. Methods: This is a single institution retrospective cohort study of patients diagnosed with endometrial cancer between 2014-2017. Statin use was defined as patients with initiation of therapy prior to the initial date of surgery or within 30 days postoperatively. Demographic, clinicopathologic, and treatment data were collected from the medical record. Proportional variables were compared using Chi-square and Fisher’s exact tests, while continuous variables were compared using t-tests and Mann-Whitney U-tests. Disease-specific survival (DSS, time from diagnosis to death due to cancer) was estimated using Kaplan-Meier plots, with log-rank and Cox proportional hazards analysis used to compare groups. Results: 765 patients were diagnosed with endometrial cancer and met inclusions criteria. 273 patients were taking a statin at the time of their diagnosis. Most patients were white race (n=704, 92.0%), diagnosed with FIGO grade 1 endometrial cancer (n=523, 68.3%), endometrioid histology (n=667, 87.2%), stage I disease (n=612, 80.0%), MMR proficient status (n=571, 74.6%). Overall, 86.1% (n=659) patients did not have disease recurrence and 67.6% (n=517) did not require adjuvant therapy following surgery. When compared with those who did not use statins, the statin group was older with an average age of 65.0 (SD +/- 9.3, p=<0.0001). BMI, race, FIGO grade, histology, stage, MMR status, recurrence, and adjuvant therapy were not statistically significant between the two groups. Most patients who took statins had a duration of use of >5 years surrounding the study period (70.7%). On multivariate analysis, there was no effect on DSS (HR 0.71 [0.35-1.35], p=0.3025) after adjusting for the above factors. Conclusions: Treatment with statins at the time of endometrial cancer diagnosis did not impact DSS in our cohort. Further studies are needed to elucidate the mechanism of cancer risk reduction of statin therapy and its effect on different cancer types, including endometrial cancer.